Show simple item record

dc.contributor.authorGillen, Sarah L
dc.contributor.authorWaldron, Joseph A
dc.contributor.authorBushell, Martin
dc.date.accessioned2021-11-12T18:56:20Z
dc.date.available2021-11-12T18:56:20Z
dc.date.issued2021-11
dc.date.submitted2021-07-16
dc.identifier.issn0950-9232
dc.identifier.others41388-021-02022-x
dc.identifier.other2022
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330605
dc.description.abstractA key characteristic of cancer cells is their increased proliferative capacity, which requires elevated levels of protein synthesis. The process of protein synthesis involves the translation of codons within the mRNA coding sequence into a string of amino acids to form a polypeptide chain. As most amino acids are encoded by multiple codons, the nucleotide sequence of a coding region can vary dramatically without altering the polypeptide sequence of the encoded protein. Although mutations that do not alter the final amino acid sequence are often thought of as silent/synonymous, these can still have dramatic effects on protein output. Because each codon has a distinct translation elongation rate and can differentially impact mRNA stability, each codon has a different degree of 'optimality' for protein synthesis. Recent data demonstrates that the codon preference of a transcriptome matches the abundance of tRNAs within the cell and that this supply and demand between tRNAs and mRNAs varies between different cell types. The largest observed distinction is between mRNAs encoding proteins associated with proliferation or differentiation. Nevertheless, precisely how codon optimality and tRNA expression levels regulate cell fate decisions and their role in malignancy is not fully understood. This review describes the current mechanistic understanding on codon optimality, its role in malignancy and discusses the potential to target codon optimality therapeutically in the context of cancer.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectReview Article
dc.subject/631/67
dc.subject/631/136/2091
dc.subject/631/337/574
dc.subjectreview-article
dc.titleCodon optimality in cancer.
dc.typeArticle
dc.date.updated2021-11-12T18:56:20Z
prism.endingPage6320
prism.issueIdentifier45
prism.publicationNameOncogene
prism.startingPage6309
prism.volume40
dc.identifier.doi10.17863/CAM.78049
dcterms.dateAccepted2021-09-10
rioxxterms.versionofrecord10.1038/s41388-021-02022-x
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidGillen, Sarah L [0000-0002-0192-864X]
dc.contributor.orcidBushell, Martin [0000-0001-9938-2691]
dc.identifier.eissn1476-5594
pubs.funder-project-idBiotechnology and Biological Sciences Research Council (BB/N017005/1)
cam.issuedOnline2021-09-28


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record